<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760056</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 15101</org_study_id>
    <nct_id>NCT02760056</nct_id>
  </id_info>
  <brief_title>Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study</brief_title>
  <acronym>MST3K</acronym>
  <official_title>Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3)
      in subjects with multiple sclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, phase I, placebo controlled clinical trial of short-term high-dose thyroid
      hormone to promote remyelination in MS. Permanent clinical disability in MS is likely caused
      by the neuronal damage and degeneration that follows recurrent demyelination with progressive
      failure of remyelination. Thyroid hormone (TH) is required for central nervous system (CNS)
      myelination during development, and CNS remyelination in animal models of MS, a process
      similar to developmental myelination, has also been found to be promoted by TH. This study
      will ascertain the safety, tolerability and maximum tolerated dose of TH in people with MS,
      explore reliability for a potential signal of treatment efficacy and mechanism, and optimize
      procedures for a full scale clinical trial to evaluate the efficacy of pulsed TH for
      promotion of remyelination in MS.

      The safety and tolerability of this treatment will be assessed using subjects' self-report of
      symptoms, the validated Hyperthyroid Symptom Scale (HSS), and blood pressure measurements. a
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2016</start_date>
  <completion_date type="Actual">January 10, 2017</completion_date>
  <primary_completion_date type="Actual">January 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation with monitoring for safety and tolerability, as well as reliability of VEP testing.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, randomized, controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS</measure>
    <time_frame>1 week</time_frame>
    <description>MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reliability of Visual Evoked Potential (VEP) Testing (ICC)</measure>
    <time_frame>1 week</time_frame>
    <description>P100 latency will be compared before and after treatment with L-T3 in subjects receiving the active treatment to assess reliability of the test for future assessment of treatment effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Liothyronine (cytomel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will take matching placebo twice a day for one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine sodium</intervention_name>
    <description>Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
    <arm_group_label>Liothyronine (cytomel)</arm_group_label>
    <other_name>Cytomel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patient will receive a matching placebo to take twice daily for one week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of MS of any type

          -  Age 18 to 50 years

          -  Weight range 45-90 kg (100-200 lbs)

          -  Lesions on brain MRI

        Exclusion Criteria:

          -  History of hypo or hyperthyroidism and a normal TSH

          -  History of high blood pressure (hypertension) [

          -  Resting blood pressure greater than 150/95, resting heart rate greater than 100

          -  History of coronary artery disease or clinically significant arrhythmia, clinically
             significant abnormalities on EKG

          -  History of diabetes

          -  History of anemia or renal (kidney) disease

          -  Clinically significant abnormalities on metabolic panel or serum hematocrit below 32 %

          -  History of atrophic gastritis

          -  History of anxiety disorder or bipolar disorder

          -  Serious psychiatric or medical conditions that would preclude reliable participation
             in the study

          -  Use of illicit substances or alcohol abuse

          -  Current use of fingolimod (Gilenya)

          -  Current or prior use of mitoxantrone (Novantrone)

          -  Current use of stimulants (methylphenidate, atomoxetine,
             dextroamphetamine,phentermine)

          -  Current use of any blood thinners such as warfarin or apixaban (Aspirin is ok)

          -  Medications which would metabolized faster in the presence of thyroid hormone
             (Insulin, oral hypoglycemic agents and oral anticoagulants)

          -  Severe head tremors (which would impair the ability to perform VEPs)

          -  Present or recent use of medications that could interact with the thyroid hormone
             (iodine containing agents such as kelp supplements, amiodarone, iodinated contrast
             given for CT or xray), P450 stimulants (phenytoin, carbamazepine, phenobarbital, and
             rifampin)

          -  Corrected visual acuity worse than 20/50 in either eye or other eye issues that would
             prevent reading of a standard eye chart

          -  Head tremors or other tremors that would prevent sitting relatively still for a vision
             test

          -  Patients taking proton pump inhibitors (PPIs) or H2 blockers will be excluded unless
             they can safely not take these medications during the week of study drug
             administration.

          -  Patients taking Ampyra (dalfampridine) will be excluded unless they can safely not
             take these medications during the week of study drug administration.

          -  Pregnancy, breastfeeding, or intention to become pregnant in the following month

          -  Inability to receive an MRI (e.g. implanted metal device)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Cameron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>May 15, 2017</results_first_submitted>
  <results_first_submitted_qc>May 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2018</results_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Michelle Cameron</investigator_full_name>
    <investigator_title>Chair and Roy &amp; Eulalia Swank Family Research Professor</investigator_title>
  </responsible_party>
  <keyword>Thyroid hormone</keyword>
  <keyword>Remyelination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liothyronine (Cytomel)</title>
          <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. If the study is fully enrolled, each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subject will take matching placebo twice a day for one week
Placebo: Patient will receive a matching placebo to take twice daily for one week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liothyronine (Cytomel)</title>
          <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subject will take matching placebo twice a day for one week
Placebo: Patient will receive a matching placebo to take twice daily for one week.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="30" upper_limit="49"/>
                    <measurement group_id="B2" value="38.4" lower_limit="21" upper_limit="46"/>
                    <measurement group_id="B3" value="38.8" lower_limit="21" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS Subtype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Relapsing Remitting Multiple Sclerosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Progressive Multiple Sclerosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS</title>
        <description>MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation)</description>
        <time_frame>1 week</time_frame>
        <population>Participants with MS taking L-T3 (10) excluding those taking placebo (5)</population>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine (Cytomel)</title>
            <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS</title>
          <description>MTD per protocol (dose level one category below dose at which study was stopped due to intolerance or meeting criteria for cessation)</description>
          <population>Participants with MS taking L-T3 (10) excluding those taking placebo (5)</population>
          <units>mcg daily with BID dosing</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reliability of Visual Evoked Potential (VEP) Testing (ICC)</title>
        <description>P100 latency will be compared before and after treatment with L-T3 in subjects receiving the active treatment to assess reliability of the test for future assessment of treatment effect.</description>
        <time_frame>1 week</time_frame>
        <population>Participants with MS taking L-T3 or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine (Cytomel)</title>
            <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will take matching placebo twice a day for one week
Placebo: Patient will receive a matching placebo to take twice daily for one week.</description>
          </group>
          <group group_id="O3">
            <title>All Participants</title>
            <description>Measure value across cohorts.</description>
          </group>
        </group_list>
        <measure>
          <title>Reliability of Visual Evoked Potential (VEP) Testing (ICC)</title>
          <description>P100 latency will be compared before and after treatment with L-T3 in subjects receiving the active treatment to assess reliability of the test for future assessment of treatment effect.</description>
          <population>Participants with MS taking L-T3 or placebo</population>
          <units>Intraclass Coefficient (ICC)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICC - Right Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.852"/>
                    <measurement group_id="O2" value="0.679"/>
                    <measurement group_id="O3" value="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC - Left Eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.746"/>
                    <measurement group_id="O2" value="0.966"/>
                    <measurement group_id="O3" value="0.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICC- Mixed Model</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889"/>
                    <measurement group_id="O2" value="0.963"/>
                    <measurement group_id="O3" value="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liothyronine (Cytomel)</title>
          <description>Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patient will receive a matching placebo to take twice daily for one week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Yellow stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <description>Back and Leg pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Poor Sleep</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased severity in post-Tecfidera flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Self-reporting of BP, HR. 1 missed dose in the drug arm. VEP testing was conducted by multiple technicians and read by multiple attending physicians; though visit one and two were more often conducted by the same tech/attending.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anna Orban</name_or_title>
      <organization>OHSU</organization>
      <phone>503-494-3549</phone>
      <email>orban@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

